Сeftazidime/avibactam in the treatment of exacerbation of a chronic respiratory infection in patients with cystic fibrosis: dynamics of clinical, microbiological, and functional parameters

Multidrug resistance of pulmonary pathogens in patients with cystic fibrosis (CF) requires new therapeutic solutions. The aim . To assess the effect ceftazidime/avibactam (cef/avi) on clinical outcomes exacerbation fibrosis. Methods This open single-group observational prospective non-interventional study was conducted routine practice settings. Patients over 18 years a confirmed diagnosis CF and an infection were included into after physician’s decision to prescribe cef/avi. examinations performed at baseline Days 5 7, 21, 30. Results analysis data from 32 patients, 12 (38%) males 20 (63%) females. mean age 31.6 years. Symptoms persisted 97 % 7 therapy only 3% Day 21. FEV 1 , FVC, SpO 2 also improved by 21 (all – p < 0.001). By proportion CRP above 10 mg/ml grew 71 9%. average density sputum contamination decreased 7.2 5.5 CFU/ml. Quality life according Cystic Fibrosis QuestionnaireRevised (CFQ-R) questionnaire improved. Conclusion In CF, lung most cases is caused multidrug resistant strains Pseudomonas aeruginosa sometimes combination Staphylococcus aureus. Infectious agents (P. aeruginosa) remain highly sensitive cef/avi (up 91%) this population so justifies use treatment exacerbation. administration led relief symptoms 97% as well significant improvement spirometry parameters, increase oxygenation index, decrease contamination, quality life. not associated lethal outcomes, ICU admission, or serious adverse drug reactions.